Quin­tiles­IMS an­a­lysts fore­cast a wave of new drug ap­provals by '22, dom­i­nat­ed by can­cer and or­phan ther­a­pies

To hear an­a­lysts at the Quin­tiles­IMS In­sti­tute tell it, 2016’s sud­den plunge in new drug ap­provals was an aber­ra­tion that won’t be re­peat­ed any­time over …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.